Issue 3/2020
Content (32 Articles)
Effects of chemotherapy on placental development and function using in vitro culture of human primary cytotrophoblasts
Christophe Louis Depoix, Arthur Colson, Mina Mhallem-Gziri, Corinne Hubinont, Frederic Debieve
Novel thiosemicarbazones induce high toxicity in estrogen-receptor-positive breast cancer cells (MCF7) and exacerbate cisplatin effectiveness in triple-negative breast (MDA-MB231) and lung adenocarcinoma (A549) cells
Estefany Ingrid Medina-Reyes, Marco Antonio Mancera-Rodríguez, Norma Laura Delgado-Buenrostro, Adriana Moreno-Rodríguez, Juan Luis Bautista-Martínez, Clara Estela Díaz-Velásquez, Stefanía Andrea Martínez-Alarcón, Hugo Torrens, María de los Ángeles Godínez-Rodríguez, Luis Ignacio Terrazas-Valdés, Yolanda Irasema Chirino, Felipe Vaca-Paniagua
The influence of the coadministration of the p-glycoprotein modulator elacridar on the pharmacokinetics of lapatinib and its distribution in the brain and cerebrospinal fluid
Agnieszka Karbownik, Katarzyna Sobańska, Włodzimierz Płotek, Tomasz Grabowski, Agnieszka Klupczynska, Szymon Plewa, Edmund Grześkowiak, Edyta Szałek
CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells
Jelena Dinić, Carla Ríos-Luci, Ieva Karpaviciene, Inga Cikotiene, Miguel X. Fernandes, Milica Pešić, José M. Padrón
Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma
Yanrong Li, Kai Wang, Na Song, Kezuo Hou, Xiaofang Che, Yang Zhou, Yunpeng Liu, Jingdong Zhang
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms
Xing Hao, Wen Xing, Jiajia Yuan, Yingshao Wang, Jiaojiao Bai, Jie Bai, Yuan Zhou
Anticancer activity of a novel methylated analogue of L-mimosine against an in vitro model of human malignant melanoma
Sotiris Kyriakou, Melina Mitsiogianni, Theodora Mantso, William Cheung, Stephen Todryk, Stephany Veuger, Aglaia Pappa, David Tetard, Mihalis I. Panayiotidis
Tetra-substituted pyrrole derivatives act as potent activators of p53 in melanoma cells
Maria Chiara Proto, Donatella Fiore, Giovanni Forte, Paola Cuozzo, Anna Ramunno, Caterina Fattorusso, Patrizia Gazzerro, Maria Pascale, Silvia Franceschelli
Vitamin K3 thio-derivative: a novel specific apoptotic inducer in the doxorubicin-sensitive and -resistant cancer cells
Mohamed-Elamir F. Hegazy, Masashi Fukaya, Mona Dawood, Ge Yan, Anette Klinger, Edmond Fleischer, Asmaa W. Zaglool, Thomas Efferth
Xanthan gum-based hydrogel containing nanocapsules for cutaneous diphenyl diselenide delivery in melanoma therapy
Luana Mota Ferreira, Marcel Henrique Marcondes Sari, Juliana Hofstatter Azambuja, Elita Ferreira da Silveira, Verônica Ferrari Cervi, Marila Crivellaro Lay Marchiori, Silvya Stuchi Maria-Engler, Marcia Rosângela Wink, Jéssica Gonçalves Azevedo, Cristina Wayne Nogueira, Elizandra Braganhol, Letícia Cruz
In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101
Laura Masuelli, Monica Benvenuto, Valerio Izzi, Erika Zago, Rosanna Mattera, Bruna Cerbelli, Vito Potenza, Sara Fazi, Sara Ciuffa, Ilaria Tresoldi, Enrico Lucarelli, Andrea Modesti, Roberto Bei
Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma
Lucy Swift, Chunfen Zhang, Olga Kovalchuk, Jessica Boklan, Tanya Trippett, Aru Narendran
A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction
Mohammadali Soleimani Damaneh, Jian-Ping Hu, Xia-Juan Huan, Shan-Shan Song, Chang-Qing Tian, Dan-Qi Chen, Tao Meng, Yue-Lei Chen, Jing-Kang Shen, Bing Xiong, Ze-Hong Miao, Ying-Qing Wang
LncRNA differentiation antagonizing non-protein coding RNA promotes proliferation and invasion through regulating miR-135a/NLRP37 axis in pancreatic cancer
Yong Tang, Guojun Cao, Gang Zhao, Chunyou Wang, Qi Qin
T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting
Xin Sun, Yang Yu, Li Ma, Xin Xue, Zhenkui Gao, Juan Ma, Man Zhang
Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells
João Agostinho Machado-Neto, Juan Luiz Coelho-Silva, Fábio Pires de Souza Santos, Priscila Santos Scheucher, Paulo Vidal Campregher, Nelson Hamerschlak, Eduardo Magalhães Rego, Fabiola Traina
Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists
Laura Muñoz-Moreno, María J. Carmena, Andrew V. Schally, Juan C. Prieto, Ana M. Bajo
Discovery of a novel rhein-SAHA hybrid as a multi-targeted anti-glioblastoma drug
Jingkao Chen, Bingling Luo, Shijun Wen, Rongbiao Pi
Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors
Mingxiang Liao, Simon Watkins, Eileen Nash, Jeff Isaacson, Jeff Etter, Jeri Beltman, Rong Fan, Li Shen, Abdul Mutlib, Vendel Kemeny, Zsuzsanna Pápai, Pascal van Tilburg, Jim J. Xiao
Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects—results from the POUDER pilot study
Vladimir J. Lozanovski, Georgios Polychronidis, Wolfgang Gross, Negin Gharabaghi, Arianeb Mehrabi, Thilo Hackert, Peter Schemmer, Ingrid Herr
Targeting ROS overgeneration by N-benzyl-2-nitro-1-imidazole-acetamide as a potential therapeutic reposition approach for cancer therapy
Rodrigo C. Zeferino, Nádia S. R. S. Mota, Valdelúcia M. A. S. Grinevicius, Karina B. Filipe, Paola M. Sulis, Fátima R. M. B. Silva, Danilo W. Filho, Claus T. Pich, Rozangela C. Pedrosa
Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
Marcus Noel, Eileen M. O’Reilly, Brian M. Wolpin, David P. Ryan, Andrea J. Bullock, Carolyn D. Britten, David C. Linehan, Brian A. Belt, Eric C. Gamelin, Bishu Ganguly, Donghua Yin, Tenshang Joh, Ira A. Jacobs, Carrie T. Taylor, Maeve A. Lowery
Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study
Su Young Jung, Sunjin Hwang, Jeffery M. Clarke, Todd M. Bauer, Vicki L. Keedy, Hukeun Lee, Neunggyu Park, Seong-Jin Kim, Jangik I. Lee
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
S. Lindsey Davis, Dana B. Cardin, Safi Shahda, Heinz-Josef Lenz, Efrat Dotan, Bert H. O’Neil, Ann M. Kapoun, Robert J. Stagg, Jordan Berlin, Wells A. Messersmith, Steven J. Cohen
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
W. Larry Gluck, Mrinal M. Gounder, Richard Frank, Ferry Eskens, Jean Yves Blay, Philippe A. Cassier, Jean-Charles Soria, Sant Chawla, Vincent de Weger, Andrew J. Wagner, David Siegel, Filip De Vos, Erik Rasmussen, Haby A. Henary
Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma
Shahneen Sandhu, Catriona M. McNeil, Patricia LoRusso, Manish R. Patel, Omar Kabbarah, Chunze Li, Sandra Sanabria, W. Michael Flanagan, Ru-Fang Yeh, Flavia Brunstein, Denise Nazzal, Rodney Hicks, Vanessa Lemahieu, Raymond Meng, Omid Hamid, Jeffrey R. Infante
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors
Mark N. Stein, Susan Goodin, Murugeson Gounder, Darlene Gibbon, Rebecca Moss, Daniella Portal, Diana Lindquist, Yujie Zhao, Naoko Takebe, Antoinette Tan, Joseph Aisner, Hongxia Lin, Neal Ready, Janice M. Mehnert
A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy
Byeong Seok Sohn, Jae Ho Jeong, Jin-Hee Ahn, Kyung Hae Jung, Jeong Eun Kim, Joo Hyuk Sohn, Su-Jin Koh, Jae Hong Seo, Keun Seok Lee, Sung-Bae Kim
Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer
Weiwei Tan, Nagdeep Giri, Susan Quinn, Keith Wilner, Kourosh Parivar
Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
Taihei Ono, Satoshi Igawa, Shintaro Kurahayashi, Yuriko Okuma, Ai Sugimoto, Seiichiro Kusuhara, Takahiro Ozawa, Tomoya Fukui, Jiichiro Sasaki, Hisashi Mitsufuji, Masanori Yokoba, Masaru Kubota, Masato Katagiri, Katsuhiko Naoki
Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer
Nikita M. Volkov, Grigoriy A. Yanus, Alexandr O. Ivantsov, Fedor V. Moiseenko, Olga G. Matorina, Ilya V. Bizin, Vladimir M. Moiseyenko, Evgeny N. Imyanitov
Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours
Bárbara dos Santos Passaia, Keli Lima, Jean Lucas Kremer, Barbara Brito da Conceição, Beatriz Marinho de Paula Mariani, Jean Carlos Lipreri da Silva, Maria Claudia Nogueira Zerbini, Maria Candida Barisson Villares Fragoso, João Agostinho Machado-Neto, Claudimara Ferini Pacicco Lotfi